This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 12, 2021
Fujifilm Irvine Scientific Expands Cell Culture R&D Center
Author(s)BioPharm International Editors
Fujifilm is expanding its R&D footprint at its California facility.
Advertisement
Fujifilm is expanding its Armstrong R&D Center of Excellence at its headquarters in California, the company announced in a Nov. 10, 2021, press release. The expansion supports Fujifilm Irvine Scientific’s discovery research and its specialty media, technologies, and custom media services.
“With society’s increasing demand for global access to more high-quality, cost-effective vaccines, biopharmaceuticals, cell-based therapies, gene therapies, and in-vitro fertilization procedures, the need for a broadened focus on innovation is pivotal to expedite critical product and technology development,” said Bob Newman, chief scientific officer, Fujifilm Irvine Scientific, in the press release. “The expansion project will more than double the R&D facility’s footprint and will allow for more enhanced technical collaboration between R&D experts and customers to develop personalized solutions and enhance partnership opportunities.”
The expansion supports the company’s initiatives in manufacturing sciences and technologies, single-use technology development, and automation platforms for media development. The expanded footprint will also include dedicated space for analytical chemistry, virology, assisted reproductive technology, and cell-culture and molecular-based assay development. Facility construction began in October and is planned for completion by January 2022. The company expects to double its R&D headcount by the close of 2022.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5